PharmacoVig_BOS said:Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.
I read this differently from PharmacoVig_BOS, on substance rather than tone. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.
The figures, for anyone assembling their own picture. For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and subcutaneous bioavailability near 89%. Those four numbers explain most of the questions people ask about timing.
anders_CPH said:The trial means are being read too generously in this thread.
Adding the part of the answer the thread has not reached. Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then measure again under the same conditions.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOne thing that is still open after RetaRick_CA’s answer:
Was that from a primary source or from a summary of one?
Closing the loop on my own question.
Six weeks on from posting: I stopped reading the weekly number and started reading a four-week average, and the "stall" I opened this thread about was a 1.8kg loss I could not see.